[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-342943-105":3,"detail-sidebar-cat-0-en-105":85,"doc-detail-342943-en":134},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":78,"head_meta":80,"extra_data":82,"updated_unix":84},105,"en","significance-of-multi-cancer-genome-profiling-testing-for-breast-cancer-a-retrospective-analysis-of-3326-cases-from-japans-national-database","Significance of Multi-Cancer Genome Profiling Testing for Breast Cancer - A Retrospective Analysis of 3326 Cases from Japan’s National Database","","Breast cancer remains the leading cause of cancer morbidity among women and ranks second for mortality. Multi-cancer genome profiling (multi-CGP) has become clinically available, and this retrospective analysis evaluates its significance using Japan’s C-CAT profiling database. From 3744 extracted cases, 3326 with ER, PR, and HER2 data were classified into TNBC, HR+/HER2−, HR+/HER2+, and HR−/HER2+. Across all cases, recurrent abnormalities included TP53 and PIK3CA, with TMB-High detected in 12.3%. Treatment suggestions based on six actionable genes showed improved prognosis for HR+/HER2− patients, supporting multi-gene panel testing as clinically useful.",{"@graph":14,"@context":77},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/significance-of-multi-cancer-genome-profiling-testing-for-breast-cancer-a-retrospective-analysis-of-3326-cases-from-japans-national-database/342943/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/significance-of-multi-cancer-genome-profiling-testing-for-breast-cancer-a-retrospective-analysis-of-3326-cases-from-japans-national-database/342943.png","ImageObject",300,407,{"name":42,"@type":43},"Aria","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-06","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73],{"name":60,"@type":61,"acceptedAnswer":62},"What is the study’s main goal regarding multi-CGP testing?","Question",{"text":63,"@type":64},"To clarify the clinical significance of multi-cancer genome profiling testing for breast cancer using a large Japanese dataset from the C-CAT profiling database.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were the 3326 breast cancer cases classified?",{"text":68,"@type":64},"Cases were categorized into four subtypes based on ER, PR, and HER2 status: TNBC, HR+/HER2−, HR+/HER2+, and HR−/HER2+.",{"name":70,"@type":61,"acceptedAnswer":71},"Which genetic alterations and biomarkers were most frequently observed?",{"text":72,"@type":64},"TP53 (58.0%) and PIK3CA (35.5%) were among the most frequent alterations; TMB-High occurred in 12.3% of cases and MSI-High in 0.3%.",{"name":74,"@type":61,"acceptedAnswer":75},"What conclusion did the results support for treatment selection?",{"text":76,"@type":64},"Cancer gene panel testing was suggested to be useful, particularly because treated HR+/HER2− patients showed significantly better prognoses than untreated patients.","https://schema.org",{"og:url":32,"og:type":79,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":81,"canonical":32},"index,follow",{"doc_id":83,"site_id":7},342943,1790192912,{"code":4,"msg":86,"data":87},"success",[88,92,96,100,105,110,114,118,123,126,130],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Exam",70,"exam",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},5,"Comic",60,"comic",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":111,"show_sort_weight":112,"slug":113},"Healthcare",40,"healthcare",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":116,"slug":117},8,30,"research-report",{"id":119,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":121,"slug":122},9,"Religion & Spirituality",20,"religion-spirituality",{"id":121,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":121,"slug":125},"World Cup","world-cup",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":127,"slug":129},10,"Lifestyle","lifestyle",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":101,"slug":133},19,"General","general",{"code":4,"msg":86,"data":135},{"doc_id":83,"user_id":136,"nickname":42,"user_avatar":137,"doc_module":4,"category_id":115,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":127,"language":143,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":12,"update_tm":147,"read_time":148,"preview_page_count":33,"preview_urls":149},2336464648322,"https://ap-avatar.wpscdn.com/avatar/2200025388227c56fec?_k=1778556882303663488","Article  \nSignificance of Multi-Cancer Genome Profiling Testing for Breast Cancer: A Retrospective Analysis of 3326 Cases from Japan’s National Database  \nKyoka Kawabata 1, Hinano Nishikubo 1, Saki Kanei 1, Rika Aoyama 1, Yuki Tsukada 1, Tomoya Sano 1,  \nDaiki Imanishi 1, Takashi Sakuma 1, Koji Maruo 1, Yurie Yamamoto 1, Qiang Wang 1, Zhonglin Zhu 1, Canfeng Fan 1 and Masakazu Yashiro 1,2, *  \nCitation: Kawabata, K.; Nishikubo, H.; Kanei, S.; Aoyama, R.; Tsukada, Y.; Sano, T.; Imanishi, D.; Sakuma, T.; Maruo, K.; Yamamoto, Y.; et al. Significance of Multi-Cancer Genome Profiling Testing for Breast Cancer: A Retrospective Analysis of 3326 Cases from Japan’s National Database.  \nGenes 2024, 15, 792. [https://doi.org/](https://doi.org/)[ ](https://doi.org/)[10.3390/genes15060792](10.3390/genes15060792)  \nAcademic Editor: Sudheer Kumar Gara  \nReceived: 13 May 2024  \nRevised: 5 June 2024  \nAccepted: 12 June 2024  \nPublished: 17 June 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Department of Molecular Oncology and Therapeutics, Osaka Metropolitan University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan; [sn23131y@st.omu.ac.jp](sn23131y@st.omu.ac.jp) (K.K.); [sn23089k@st.omu.ac.jp](sn23089k@st.omu.ac.jp) (H.N.); [sn23107b@st.omu.ac.jp](sn23107b@st.omu.ac.jp) (S.K.); [si22406x@st.omu.ac.jp](si22406x@st.omu.ac.jp) (R.A.); [sr24464c@st.omu.ac.jp](sr24464c@st.omu.ac.jp) (Y.T.); [sb24524y@st.omu.ac.jp](sb24524y@st.omu.ac.jp) (T.S.); [stuck.on.alizee@gmail.com](stuck.on.alizee@gmail.com) (D.I.); [so22500y@st.omu.ac.jp](so22500y@st.omu.ac.jp) (T.S.); [k.maruo0720@gmail.com](k.maruo0720@gmail.com) (K.M.); [yurieyamamoto917@gmail.com](yurieyamamoto917@gmail.com) (Y.Y.); [qiangw@vip.126.com](qiangw@vip.126.com) (Q.W.); [zhuzhonglin1992@163.com](zhuzhonglin1992@163.com) (Z.Z.); [fancanfeng@gmail.com](fancanfeng@gmail.com) (C.F.)  \n2 Cancer Center for Translational Research, Osaka Metropolitan University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan  \n* Correspondence: [i21496f@omu.ac.jp](i21496f@omu.ac.jp); Tel.: +81-6-6645-3936  \nAbstract: Background: Breast cancer (BC) has the highest morbidity rate and the second-highest mortality rate of all cancers among women. Recently, multi-cancer genome profiling (multi-CGP) tests have become clinically available. In this study, we aimed to clarify the significance of multiCGP testing of BC by using the large clinical dataset from The Center for Cancer Genomics and Advanced Therapeutics (C-CAT) profiling database in Japan. Materials and Methods: A total of 3744 BC cases were extracted from the C-CAT database, which enrolled 60,250 patients between June 2019 and October 2023 . Of the 3744 BC cases, a total of 3326 cases for which the C-CAT included information on ER, PR, and HER2 status were classified into four subtypes, including TNBC, HR+/HER2−, HR+/HER2+, and HR−/HER2+ . Comparisons between groups were performed by the χ2 test or Fisher’s exact test using EZR. Kaplan–Meier curves were created using the log-rank test. Results: Of all 3326 cases analyzed, 1114 (33.5%) were TNBC cases, HR+/HER2 − accounted for 1787 cases (53.7%), HR+/HER2+ for 260 cases (7.8%), and HR−/HER2+ for 165 cases (5.0%) . Genetic abnormalities were most frequently detected in TP53 (58.0%), PIK3CA (35.5%), MYC (18.7%), FGF19 (15.5%), and GATA3 (15.1%) across all BCs. The rate of TMB-High was 12.3%, and the rate of MSIHigh was 0.3%, in all BC cases. Therapeutic drugs were proposed for patients with mutations in six genes: PIK3CA, ERBB2, PTEN, FGFR1, ESR1, andAKT1 . The prognoses of HR+/HER2 − cases were significantly (p = 0.044) better in the t","cbCaiqR9JGttXqWk","https://ap.wps.com/l/cbCaiqR9JGttXqWk","pdf",1230855,"English","# Abstract\n## Background and Aim\n## Materials and Methods\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"What is the study’s main goal regarding multi-CGP testing?\",\"answer\":\"To clarify the clinical significance of multi-cancer genome profiling testing for breast cancer using a large Japanese dataset from the C-CAT profiling database.\"},{\"question\":\"How were the 3326 breast cancer cases classified?\",\"answer\":\"Cases were categorized into four subtypes based on ER, PR, and HER2 status: TNBC, HR+/HER2−, HR+/HER2+, and HR−/HER2+.\"},{\"question\":\"Which genetic alterations and biomarkers were most frequently observed?\",\"answer\":\"TP53 (58.0%) and PIK3CA (35.5%) were among the most frequent alterations; TMB-High occurred in 12.3% of cases and MSI-High in 0.3%.\"},{\"question\":\"What conclusion did the results support for treatment selection?\",\"answer\":\"Cancer gene panel testing was suggested to be useful, particularly because treated HR+/HER2− patients showed significantly better prognoses than untreated patients.\"}]","Significance of Multi-Cancer Genome Profiling Testing for Breast Cancer - A Retrospective Analysis of 3326 Cases from Japan’s National Database | PDF",1790048990,25,[150,154,158,162],{"page_no":22,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/87ecf110add5a8f23377521d24daab2e.webp",983,1390,{"page_no":26,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/388a0524ccfd029d60884015b5a3a0c3.webp",982,1388,{"page_no":30,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/176d6ac1bcf413f4ff21548031e3028e.webp",981,1387,{"page_no":33,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/69a24cab121bfc11b4e19edd6fa45e76.webp",980,1385]